The drug is an alternative to opiates.
Novel prodrug with unique mechanism of action takes on the opioid crisis
True North is a Mission Bay Capital portfolio company pursuing therapies that target the complement system to treat rare diseases.
Symic recently graduated from the QB3@953 incubator after several years' residence.
Principia is a spinoff from Jack Taunton’s lab at UCSF.
Principia plans to list on the Nasdaq under the symbol PRNB.
The collaboration is aimed at developing first-in-class oral therapies that bring the power of proteasome inhibition safely into the field of immunology.
eFFECTOR, in Mission Bay Capital's portfolio, is a leader in the development of selective translation regulators for the treatment of cancer.
eFT508 and avelumab are immunotherapies, designed to harness the body's own immune system in fighting cancer.
Atreca uses its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types.
Atreca was one of the first companies in Mission Bay Capital’s portfolio.
Atreca was an early portfolio company of QB3-affiliated Mission Bay Capital.
Atreca will apply its Immune Repertoire Capture® technology to generate sequences of native antibodies and TCRs from patients.
Sillajen is a former resident of the Mission Bay Innovation Center.
The collaboration will advance polypharmacology in drug discovery using AI-augmented technology.
The partnership will develop intravitreal gene therapeutics for patients using 4DMT-proprietary AAV vectors.
The financing will help the company advance its Smart Growth Factor™ pipeline into the clinic.
In the San Francisco Business Times’s annual survey.
Grifols, based in Spain, is set to acquire a 44% stake in GigaGen, a startup that discovers and develops pre-clinical biotherapeutics.
This will take Carmot's lead Type 2 diabetes drug through clinical proof of concept.
The firms will leverage Carmot’s Chemotype Evolution lead-identification technology.
The funding will help develop a novel polymer nanoparticle technology platform for non-viral-based delivery of gene therapeutics.
The funding will expand the team, enable clinical trials for Meissa’s investigational vaccine, and support a viral vaccine pipeline.
The Meissa team has developed a live attenuated vaccine with global utility.
Meissa was incorporated through QB3 Startup in a Box.
ViewPoint's technology prevents and treats cataracts and presbyopia.
Mark Cuban and Perlara founder Ethan Perlstein met on Twitter, where they had a conversation about drug pricing.
Novartis invested and partnered with Perlara, a resident of QB3@953, to discover and develop treatments for lysosomal storage disorders using CRISPR-engineered animal models.
Glycomine is developing orphan drugs for serious rare monogenic disorders of metabolism and protein misfolding.
Celgene bought the startup for $300 million upfront to expand its inflammation and immunology pipeline with Delinia's regulatory T cell therapy.
The company will develop new medicines to selectively potentiate and expand regulatory T cells.
Gilead reasons that the companies could treat a broader range of blood and solid cancers.
Last year, Alector advanced two drugs into early-stage clinical testing.
With this much investor interest, the round keeps Alector's options open, CBO Sabah Oney says.
The collaboration could generate up to $225 million for Alector.